NEW YORK (GenomeWeb) – Accelerate Diagnostics said on Thursday that its total revenues shot up to $122,000 in 2014 from $48,000 in 2013. 

In its Form 10-K filed with the US Securities and Exchange Commission, the company said that the increase resulted from deferred royalties recognized last year. In 2014 Accelerate recognized $69,000 in deferred revenues compared to $10,000 in 2013. 

All revenues for both years consisted of licensing and royalty revenues. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.